Coherus Refiles US On-Body Pegfilgrastim, With Potential For 2023 Approval
Company Indicates That Quick Resolution Of CRL Could Lead To FDA Nod By Year End
Coherus BioSciences has swiftly returned a filing for its on-body pegfilgrastim biosimilar candidate to the US Food and Drug Administration, while hitting a milestone for its Cimerli biosimilar to Lucentis (ranibizumab).
